Company: NCEL
Filing Date: 2025-05-16
Form Type: 20-F
Source: 0001213900-25-044868
Chunk: 349

Company: NewcelX Ltd.
Filing Date: 2025-05-16
Form: 20-F
Item: Item 19
Chunk 349
---
  Effect of exchange rate on cash and cash equivalents                                                                   -                          -                                  ( 100  
  Change in cash and cash equivalents                                                                                    767,715                    ( 8,050,720                    3,517,198  
  Cash and cash equivalents at the beginning of period                                                                   897,680                    8,948,400                      5,431,202  
  Cash and cash equivalents at the end of period                                   $                                     1,665,395        $         897,680           $            8,948,400  
  Supplemental disclosure of non-cash investing and financing activities:                                                                                                                     
  Cash paid for interest                                                           $                                     467              $         145,153           $               13,248  
  Issuance of note payable for prepaid insurance                                   $                                     -                $                           $              704,160  
  Issuance of preferred shares for the assumption of debt                          $                                     4,000,000        $         -                 $                    -  
  Issuance of common shares for debt conversion                                                                          2,788,650                                                            
  Issuance of common shares for conversion of preferred shares                                                           18,000                                                               
  Change in accrued pension liability reflected in accumulated other                                                     260,685                                                              
  Deemed dividend                                                                                                        2,076,180        $         -                 $                    -  
  Debt discount on convertible loans                                               $                                     -                $         -                 $               67,008  

The accompanying notes are an integral part of
these consolidated financial statements.

F-8

Note 1

Background:

NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) (the
“ Company”) and its wholly-owned subsidiaries NLS Pharmaceutics (Israel) Ltd., an Israeli company (the “ Merger Sub”)
and NLS Pharmaceutics Inc., a Delaware corporation, is an emerging biopharmaceutical company engaged in the discovery and development
of life-improving drug therapies to treat rare and complex central nervous system disorders, including narcolepsy, idiopathic hypersomnia
and other rare sleep disorders, and of neurodevelopmental disorders, such as attention deficit hyperactivity disorder (“ ADHD”).
The Company’s lead product candidates are Quilience, to treat narcolepsy (type 1 and type 2), and Nolazol, to treat ADHD.

The Company was established in June 2015 through
the incorporation of its predecessor entities,